# Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response

> **NCT07670715** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Locally Advanced Non-small Cell Lung Cancer (NSCLC)
- Thoracic Radiotherapy
- Immune Checkpoint Inhibitors
- Neoadjuvant Chemoimmunotherapy

## Interventions

- **RADIATION:** lattice radiation therapy

## Key facts

- **NCT ID:** NCT07670715
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670715, "Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07670715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*